Biomarkers Consortium Programs

The identification of new biomarkers is an increasingly essential element of predictive, preventive and personalized medicine. To meet this need, The Biomarkers Consortium projects serve to develop promising biomarkers in order to help accelerate the delivery of successful new technologies, medicines and therapies for prevention, early detection, diagnosis and treatment of disease.

Transforming the ability to treat Alzheimer’s disease by enabling early and reliable diagnosis
The goal of this three-year project is to validate the novel radiographic measures, MRI measures and biochemical markers from the Phase I OA Biomarkers Consortium Project, and to qualify those biomarkers via the formal regulatory qualification process with both the FDA and EMA.
Exploring opportunities to put holistic, evidence-based science into practice, shape regulatory and payer interactions, patient and human engagement, product development and embed digital measures into health care decision-making.
Establishing biomarkers to improve treatments for children with autism spectrum disorders
Developing tools to assess Americans’ risk of developing and dying from cardiovascular disease
Revolutionizing the ability to diagnose early-stage Alzheimer’s disease, and enabling earlier and more effective treatments for patients
The project seeks to analyze volumetric CT imaging trial data from completed industry phase II solid tumor trials to improve quantitative prediction of phase III results.